ABIOMED, Inc. (ABMD)

[chmcnfunds]

Abiomed Stock Rating Reaffirmed by Zacks (ABMD)

Posted by Zach Kirkland on Jan 15th, 2013 // No Comments

Zacks reaffirmed their neutral rating on shares of Abiomed (NASDAQ: ABMD) in a research note released on Tuesday morning. They currently have a $13.00 price target on the stock.

ABMD has been the subject of a number of other recent research reports. Analysts at Wunderlich reiterated a buy rating on shares of Abiomed in a research note to investors on Thursday, November 29th. They now have a $29.00 price target on the stock. Separately, analysts at Piper Jaffray reiterated an overweight rating on shares of Abiomed in a research note to investors on Wednesday, November 28th. They now have a $18.00 price target on the stock. Finally, analysts at Raymond James initiated coverage on shares of Abiomed in a research note to investors on Friday, November 9th. They set a market perform rating on the stock.

Five equities research analysts have rated the stock with a buy rating, two have given an overweight rating, two have given a hold rating, one has assigned an underweight rating, and one has given a sell rating to the company. The company currently has an average rating of overweight and an average price target of $19.50.

Shares of Abiomed traded down 1.06% during mid-day trading on Tuesday, hitting $12.19. Abiomed has a one year low of $11.80 and a one year high of $26.17. The stock’s 50-day moving average is currently $13.32. The company has a market cap of $470.9 million and a P/E ratio of 36.45.

Abiomed last announced its earnings results on Thursday, November 1st. The company reported $0.20 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.05 by $0.15. The company had revenue of $37.40 million for the quarter, compared to the consensus estimate of $37.47 million. The company’s quarterly revenue was up 26.9% on a year-over-year basis. On average, analysts predict that Abiomed will post $0.34 earnings per share for the current fiscal year.

Abiomed, Inc. is a provider of medical devices in circulatory support and offers a continuum of care in heart recovery to acute heart failure patients.

To view Zacks’ full report, visit www.zacks.com
________________________________________________________
http://www.jagsreport.com/2013/01/abiomed-stock-rating-reaffirmed-by-zacks-abmd/

ABMD